{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:36:42Z","timestamp":1769812602233,"version":"3.49.0"},"reference-count":10,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1339,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1111\/j.1529-8019.2012.01433.x","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T14:37:26Z","timestamp":1337179046000},"page":"95-97","source":"Crossref","is-referenced-by-count":15,"title":["Pemphigus vulgaris treated with adalimumab: case study"],"prefix":"10.1155","volume":"25","author":[{"given":"NAD\u011b\u017eDA","family":"VOJ\u00e1\u010dKOV\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JORGA","family":"FIALOV\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DANIELA","family":"VA\u0148OUSOV\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JANA","family":"HERCOGOV\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2012,5,16]]},"reference":[{"issue":"6","key":"10.1111\/j.1529-8019.2012.01433.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2012.01433.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1172\/JCI200524855","article-title":"The pathophysiology of autoimmune blistering diseases","volume":"115","author":"Yancey","year":"2005","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01433.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/tcrm.2007.3.1.29","article-title":"Therapy of autoimmune bullous diseases","volume":"3","author":"Mutasim","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01433.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1529-8019.2008.01213.x","article-title":"Long-term efficacy of biologics in dermatology","volume":"22","author":"Castelo-Soccio","year":"2009","journal-title":"Dermatol Ther"},{"issue":"10","key":"10.1111\/j.1529-8019.2012.01433.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/11316810-000000000-00000","article-title":"Novel therapies for pemphigus vulgaris","volume":"26","author":"Perez","year":"2009","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1111\/j.1529-8019.2012.01433.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0019-5154.53175","article-title":"Biologics: target - specific treatment of systemic and cutaneous autoimmune diseases","volume":"54","author":"Raychaudhuri","year":"2009","journal-title":"Indian J Dermatol"},{"key":"10.1111\/j.1529-8019.2012.01433.x-BIB7|cit7","first-page":"224","article-title":"Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus - an update","volume":"15","author":"Arin","year":"2005","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01433.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1365-2133.2005.06744.x","article-title":"Rapid control of therapy - refractory pemphigus vulgaris by treatment with tumour necrosis factor alpha inhibitor infliximab","volume":"153","author":"Jacobi","year":"2005","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2012.01433.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2133.2005.06672.x","article-title":"Infliximab in the management of severe pemphigus vulgaris","volume":"155","author":"Pardo","year":"2005","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1111\/j.1529-8019.2012.01433.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/archderm.141.6.680","article-title":"Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxine laser","volume":"141","author":"Lin","year":"2005","journal-title":"Arch Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2012.01433.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2012.01433.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:58:44Z","timestamp":1671818324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2012.01433.x"}},"subtitle":["Pemphigus vulgaris treated with adalimumab"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2012.01433.x","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}